Croda International plc (CRDA.L) - Company Research

Last Updated: 2 May 2026

Croda International plc (LSE: CRDA) is a 100-year-old British FTSE 100 speciality chemicals company headquartered at Cowick Hall in Snaith, East Yorkshire. Croda creates high-performance ingredients for three end markets: Consumer Care (beauty, personal care, fragrance, home care), Life Sciences (pharma drug-delivery lipids, crop protection, seed enhancement) and Industrial Specialities. FY2025 (calendar year) revenue was £1,699.4 m (+6.6% constant currency, +4.4% reported), adjusted operating profit £295.3 m (+7.9% cc) at a 17.4% margin, free cash flow £161.6 m, and net debt £523.8 m (1.3× EBITDA). The FY2025 dividend was 111.0p (interim 48.0p + final 63.0p) — the 33rd consecutive year of progression. The Q1 2026 trading update on 22 April 2026 reported sales of £431 m, +1% constant currency (−2% reported), Consumer Care +4%, Life Sciences −3% (Crop Protection −8% as the H1 25 inventory rebuild reversed), Industrial Specialities −2%, with FY26 guidance unchanged. Croda also opened a new £55 m greenfield manufacturing plant in Dahej, Gujarat (India) on 19 March 2026 — the largest UK chemical investment in India. The next event in the calendar is the FY2025 final dividend payment of 63.0p on 27 May 2026; H1 2026 results follow on 28 July 2026. For live pricing see our live charts, upcoming releases on the economic calendar, and discussion on the ChartsView forum.

1. Company Snapshot

2. Bull Case vs Bear Case

3. What Does This Company Actually Do?

Croda creates speciality ingredients that are formulated into customers' end products and effectively "specced-in" by formulation chemists, generating sticky customer relationships. The strategic emphasis since the 2022 PTIC divestment has been the three structural-growth end-markets — Consumer, Pharma and Agriculture — which together account for 89% of FY25 sales.

FY2025 segment revenue split (£1,699.4 m total):

• Consumer Care — £972.7 m (~57%) — Beauty Actives +6%, Beauty Care +4%, Fragrances & Flavours +15%, Home Care +2% (constant currency).
• Life Sciences — £532.2 m (~31%) — Pharma +4%, Crop Protection +14%, Seed Enhancement +8%; includes Avanti Polar Lipids drug-delivery business.
• Industrial Specialities — £194.5 m (~12%) — weak end-markets, −2% constant currency.

4. The Business Model

Croda is a high-margin speciality formulation business, not a commodity chemical producer. Its competitive moat is built on customer co-development — Croda partners with formulators (cosmetics brands, pharma developers, agrochemical companies) to design ingredients into customer products. Once an ingredient is specced into an FDA-approved drug, an EMEA-registered crop-protection product, or a cosmetics SKU, switching costs and re-formulation timelines protect Croda's pricing.

• IP-protected ingredients: New & Protected Products (NPP) account for 35% of FY25 sales (FY24: 35%); patented ingredient sales +9% in FY25.
• Pricing power: Targeted price increases pushed through April–May 2026 with no demand pushback, per CFO Stephen Oxley on the Q1 2026 call.
• Sustainability positioning: ECO range (100% bio-based, 100% renewable non-ionic surfactants, USDA BioPreferred-certified, manufactured at Atlas Point, Delaware); >60% of palm-derivative volumes now Deforestation and Conversion Free, with a 100% target by 2030.
• Asset utilisation: 11 shared global manufacturing sites; rising utilisation in FY25 supports margin expansion.

Long-term margin trajectory (adjusted operating margin): FY21 ~24.8%, FY22 ~24.7%, FY23 18.9%, FY24 17.2%, FY25 17.4%, FY28 target >20%.

Subsidy / regulatory credit dependency: Croda received up to $75 m of US BARDA support to scale domestic mRNA / oligonucleotide lipid supply during 2025–2026. Beyond that BARDA funding stream, Croda has no material reliance on government subsidies or regulatory credits — revenue is product-sale-driven.

5. Financial Health

Five-year fiscal trend (calendar years, £ millions unless noted):

Croda reports interim (H1) and full-year results, plus Q1 and Q3 trading updates — quarterly revenue with gross margin is not separately disclosed at the level of detail required for a quarterly chart, so the bar/line visualisation is omitted by design (Section 5 chart conditional).

Q1 2026 trading update (22 April 2026): Group sales £431 m, +1% constant currency (−2% reported); Consumer Care +4%, Life Sciences −3%, Industrial Specialities −2%. Latin America +11%, EMEA +2%, Asia +2%, North America −7%. FY26 guidance unchanged; ~£4 m FX headwind to FY26 operating profit at March 2026 spot rates.

Major non-cash items in FY25: £107.3 m of impairments (including the Lamar Pennsylvania lipid plant placed on standby) and £185.2 m of total adjusting items — the reason basic EPS fell to 44.4p versus adjusted EPS of 146.2p.

6. Valuation & Market Data

7. What Are They Building / What's Coming?

• Pharma / lipids capacity: ~£150 m invested over the past five years in Lamar (Pennsylvania) and Leek (UK) lipid manufacturing. Lamar placed on standby in FY25 to manage post-Covid mRNA capacity overhang. Up to $75 m BARDA support to scale domestic mRNA / oligonucleotide supply during 2025–2026. The £175 m total Pharma investment programme is now at end-stage.
• India greenfield (Dahej, Gujarat): opened 19 March 2026 — ~£55 m / ₹691 crore. Designed for low Scope 1/2 emissions: renewable electricity, RSPO oleochemicals, Zero Liquid Discharge later in 2026. Largest UK chemical investment in India's chemical sector. Serves all three sectors.
• Sustainability / R&D: ECO range bio-based surfactants (Atlas Point, Delaware); 34.2% absolute Scope 1+2 reduction vs 2018 baseline by end-2025; NPP at 35% of revenue.
• Croda Foundation: £5.4 m committed to date; additional £1 m Centenary Fund donation in 2026; 22.8 m lives "sustainably improved" via partner projects.
• Capex outlook: £108.2 m (6% of sales) in FY25 vs £137.9 m FY24 and £170.1 m FY23. Capex to moderate further as a percentage of sales from 2026 onwards.
• 2026–2028 financial framework (set 24 February 2026): organic sales growth 3–6% CAGR, adjusted operating margin >20% by FY28, FCF/sales >12% by FY28, ROIC >10% by FY28.

8. Competitive Landscape

Croda competes across three distinct competitor pools, each with different scale dynamics. Specific named market-share percentages are not publicly disclosed at the granularity required for a single bar-chart visualisation, so Section 8 lists competitors with revenue scale rather than emitting a competitor-share SVG.

Croda's positioning emphasises patent-protected, sustainability-forward, customer-co-developed ingredients that compete on performance and IP rather than scale or price.

9. Leadership and Ownership

Board (2026): Chair Danuta Gray (since Feb 2024); Group CEO Steve Foots, CBE (since Jan 2012; awarded CBE 2025); Group CFO Stephen Oxley (since April 2025; ex-Johnson Matthey CFO and ex-KPMG ~30 years); Group General Counsel & Co-Sec Tom Brophy; Senior Independent Director Jacqui Ferguson; Non-Executives Keith Layden, Roberto Cirillo, Nawal Ouzren, Chris Good, Ian Bull, and Jill Anderson (effective January 2026).

Executive Committee (non-Board): Sandra Breene (President Consumer Care); Thomas Riermeier (President Life Sciences, ex-Evonik Health Care, joined April 2025); Anthony Fitzpatrick (President Strategy, Corporate Development & Industrial Specialities); Thiru Selvan (President Supply Chain Operations, ex-IFF, joined July 2025); Michelle Lydon (President HR).

Top institutional shareholders (most recent disclosed): Norges Bank Investment Management 7.94% (reduced from 8.32% on 1 April 2026); BlackRock among top 13 institutions; top 13 institutions hold ~50–51% combined; total institutional ownership ~77–78%.

Recent insider / PDMR transactions:

The 2025–2026 transaction stream has been dominated by routine SIP / monthly partnership-share contributions and DSBP awards — no major outright purchases or sales by directors.

10. Risks and Challenges

• Customer destocking risk: the 2023 destocking cycle hit Croda hard (adjusted PBT fell from ~£463 m FY22 pro forma to £308.8 m FY23). Q1 2026 commentary confirmed the H1 25 inventory rebuild in Crop Protection has reversed (−8% in Q1 2026).
• Pharma / Covid lipid normalisation: peak mRNA-vaccine lipid demand has unwound; Lamar (Pennsylvania) lipid plant placed on standby in FY25; large-scale capacity outstrips current pharma-pipeline needs. £107.3 m of FY25 impairments hit basic EPS.
• Currency exposure: significant USD and EUR exposure. ~£4 m FX drag on FY26 reported operating profit at March 2026 spot rates.
• Raw material costs: input-cost inflation prompted targeted price increases April–May 2026.
• Geopolitical: Middle East conflict cited in the Q1 2026 update as elevating uncertainty; trade and tariff dynamics affected Beauty Care Q1 (pre-tariff buying effects).
• China / Asia demand: historically a swing factor; in Q1 2026 Latin America was the strongest growth region rather than China.
• Palm oil / ESG: RSPO certification, Mass Balance reliance, and EU deforestation regulations (EUDR). 100% Deforestation and Conversion Free target by 2030.
• Safety performance: Total Recordable Injury Rate rose from 0.47 (2024) to 0.61 (2025), against a 0.3 target by 2026 — flagged as a setback in the 2025 KPIs.
• Margin recovery execution: FY28 >20% adjusted operating margin target requires meaningful uplift from FY25's 17.4%.
• Dividend cover: 2.2× in FY25 is reasonable but the 1p annual progression in FY24 / FY25 signals constrained dividend growth.

11. Recent Developments

• 23 April 2026 — Result of AGM (held 22 April 2026 at Milner York hotel, York) — all resolutions passed.
• 22 April 2026 — Q1 2026 trading update: sales £431 m, +1% cc (−2% reported), Consumer Care +4%, Life Sciences −3%, Industrial Specialities −2%. FY26 guidance unchanged.
• 13 April 2026 — Director/PDMR shareholding RNS (Share Incentive Plan transactions dated 10 April 2026 across six executives).
• 2 April 2026 — Norges Bank reduced its stake to 7.94% (from 8.32%).
• 19 March 2026 — Inauguration of Dahej (Gujarat, India) ~£55 m greenfield plant — largest UK chemical investment in India's chemical sector.
• 16 March 2026 — Annual Financial Report posted.
• 24 February 2026 — FY2025 results: revenue £1,699.4 m (+6.6% cc), adjusted operating profit £295.3 m (+7.9% cc), adjusted EPS 146.2p (+2.5%), DPS 111.0p (+1p). Net debt £523.8 m (1.3×). FCF £161.6 m. £107.3 m impairments. 2026–2028 financial framework launched.
• 9 January 2026 — Director Declaration (Jill Anderson appointment effective).
• 16 October 2025 — Q3 2025 sales update.
• 29 July 2025 — H1 2025 results.
• July 2025 — Thiru Selvan joined as President Supply Chain Operations.
• April 2025 — Stephen Oxley joined as CFO; Thomas Riermeier joined as President Life Sciences.

12. Key Dates Coming Up

• 27 May 2026 — Final ordinary dividend payment (63.0p; ex-div was 9 April 2026).
• 30 June 2026 — Preference dividend payment.
• 28 July 2026 — Half Year (H1 2026) results announcement.
• 6 October 2026 — Interim ordinary dividend payment.
• Mid-October 2026 (TBC) — Q3 2026 sales update (typical cadence).
• 23 February 2027 — Full Year 2026 results announcement.
• ~April 2027 — AGM.

Related links on ChartsView: live charts · economic calendar · forum · blog

Disclaimer: This research is compiled from primary sources (RNS announcements, annual report, company press releases, IR pages and direct executive communications) and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer to buy or sell any security. ChartsView holds no analyst opinions or price targets. Always do your own research and consider your personal circumstances before investing.